Engineers design bionic “heart” for testing prosthetic valves, other cardiac devices – Device made of heart tissue and a robotic pumping system beats like the real thing – Jennifer Chu | MIT News Office January 29, 2020 @ In Brief – Published: 06 July 2020 HEART FAILURE – Myosin activator improves cardiac function – Gregory B. Lim – Nature Reviews Cardiology (2020) & HEART FAILURE – Benefits of combination pharmacotherapy for HFrEF – Gregory B. Lim – Nature Reviews Cardiology (2020) @#TIME # ACCESS – INFORMATION # HEALTH – LIFE – AGE – AGES – LONGEVITY & INTERNET – COUNTRIES & VERY IMPORTANT WEBSITES, SOCIAL NETWORKS, LINKS AND IMAGES OF THE WORLD

Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!!

  • – > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics´´My´´ Dissertation @ #Innovation #energy #life #health #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World

Pathol Res Pract. 2012 Jul 15;208(7):377-81. doi: 10.1016/j.prp.2012.04.006. Epub 2012 Jun 8.

The influence of physical activity in the progression of experimental lung cancer in mice

Renato Batista Paceli 1Rodrigo Nunes CalCarlos Henrique Ferreira dos SantosJosé Antonio CordeiroCassiano Merussi NeivaKazuo Kawano NagaminePatrícia Maluf Cury


GRUPO_AF1GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 1GROUP AFAN1 – Anaerobic Physical ActivityAtividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO_AF2GROUP AFA2 – Aerobic Physical ActivityAtividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 2GROUP AFAN 2 – Anaerobic Physical ActivityAtividade Física Anaeróbia´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

Slides – mestrado´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto



Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo´´My´´ Dissertation Faculty of Medicine of Sao Jose do Rio Preto


Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.




  • A close-up of a synthetic matrix of soft robotic actuators that can be wrapped around a heart ventricle and inflated to squeeze and twist the heart in the same way a real heart pumps blood. A close-up of a synthetic matrix of soft robotic actuators that can be wrapped around a heart ventricle and inflated to squeeze and twist the heart in the same way a real heart pumps blood.Image courtesy of the researchers.
  • A preserved heart muscle (1) is removed and replaced with a soft synthetic matrix (2). The two structures (inner cardiac tissue and synthetic matrix) (3) are bonded using a newly developed adhesive, TissueSil (4). The resulting piece is the biohybrid heart containing the preserved intracardiac structures and synthetic heart muscle (5).A preserved heart muscle (1) is removed and replaced with a soft synthetic matrix (2). The two structures (inner cardiac tissue and synthetic matrix) (3) are bonded using a newly developed adhesive, TissueSil (4). The resulting piece is the biohybrid heart containing the preserved intracardiac structures and synthetic heart muscle (5).Image: Clara Park
  • A close-up of a synthetic matrix of soft robotic actuators that can be wrapped around a heart ventricle and inflated to squeeze and twist the heart in the same way a real heart pumps blood. A close-up of a synthetic matrix of soft robotic actuators that can be wrapped around a heart ventricle and inflated to squeeze and twist the heart in the same way a real heart pumps blood.Image courtesy of the researchers.
  • A preserved heart muscle (1) is removed and replaced with a soft synthetic matrix (2). The two structures (inner cardiac tissue and synthetic matrix) (3) are bonded using a newly developed adhesive, TissueSil (4). The resulting piece is the biohybrid heart containing the preserved intracardiac structures and synthetic heart muscle (5).A preserved heart muscle (1) is removed and replaced with a soft synthetic matrix (2). The two structures (inner cardiac tissue and synthetic matrix) (3) are bonded using a newly developed adhesive, TissueSil (4). The resulting piece is the biohybrid heart containing the preserved intracardiac structures and synthetic heart muscle (5).Image: Clara Park

Engineers design bionic “heart” for testing prosthetic valves, other cardiac devices

Device made of heart tissue and a robotic pumping system beats like the real thing.

Jennifer Chu | MIT News Office
January 29, 2020




As the geriatric population is expected to balloon in the coming decade, so too will rates of heart disease in the United States. The demand for prosthetic heart valves and other cardiac devices — a market that is valued at more than $5 billion dollars today — is predicted to rise by almost 13 percent in the next six years.

Prosthetic valves are designed to mimic a real, healthy heart valve in helping to circulate blood through the body. However, many of them have issues such as leakage around the valve, and engineers working to improve these designs must test them repeatedly, first in simple benchtop simulators, then in animal subjects, before reaching human trials — an arduous and expensive process.

Now engineers at MIT and elsewhere have developed a bionic “heart” that offers a more realistic model for testing out artificial valves and other cardiac devices.

The device is a real biological heart whose tough muscle tissue has been replaced with a soft robotic matrix of artificial heart muscles, resembling bubble wrap. The orientation of the artificial muscles mimics the pattern of the heart’s natural muscle fibers, in such a way that when the researchers remotely inflate the bubbles, they act together to squeeze and twist the inner heart, similar to the way a real, whole heart beats and pumps blood.

With this new design, which they call a “biorobotic hybrid heart,” the researchers envision that device designers and engineers could iterate and fine-tune designs more quickly by testing on the biohybrid heart, significantly reducing the cost of cardiac device development.

“Regulatory testing of cardiac devices requires many fatigue tests and animal tests,” says Ellen Roche, assistant professor of mechanical engineering at MIT. “[The new device] could realistically represent what happens in a real heart, to reduce the amount of animal testing or iterate the design more quickly.”

Roche and her colleagues have published their results today in the journal Science Robotics. Her co-authors are lead author and MIT graduate student Clara Park, along with Yiling Fan, Gregor Hager, Hyunwoo Yuk, Manisha Singh, Allison Rojas, and Xuanhe Zhao at MIT, along with collaborators from Nanyang Technology University, the Royal College of Surgeons in Dublin, Boston’s Children’s Hospital, Harvard Medical School, and Massachusetts General Hospital.

The structure of the biorobotic hybrid heart under magnetic resonance imaging. Credit: Christopher T. Nguyen

“Mechanics of the heart”

Before coming to MIT, Roche worked briefly in the biomedical industry, helping to test cardiac devices on artificial heart models in the lab.

“At the time I didn’t feel any of these benchtop setups were representative of both the anatomy and the physiological biomechanics of the heart,” Roche recalls. “There was an unmet need in terms of device testing.”

In separate research as part of her doctoral work at Harvard University, she developed a soft, robotic, implantable sleeve, designed to wrap around a whole, live heart, to help it pump blood in patients suffering from heart failure.

At MIT, she and Park wondered if they could combine the two research avenues, to develop a hybrid heart: a heart that is made partly of chemically preserved, explanted heart tissue and partly of soft artificial actuators that help the heart pump blood. Such a model, they proposed, should be a more realistic and durable environment in which to test cardiac devices, compared with models that are either entirely artificial but do not capture the heart’s complex anatomy, or are made from a real explanted heart, requiring highly controlled conditions to keep the tissue alive.

The team briefly considered wrapping a whole, explanted heart in a soft robotic sleeve, similar to Roche’s previous work, but realized the heart’s outer muscle tissue, the myocardium, quickly stiffened when removed from the body. Any robotic contraction by the sleeve would fail to translate sufficiently to the heart within.

Instead, the team looked for ways to design a soft robotic matrix to replace the heart’s natural muscle tissue, in both material and function. They decided to try out their idea first on the heart’s left ventricle, one of four chambers in the heart, which pumps blood to the rest of the body, while the right ventricle uses less force to pump blood to the lungs.

“The left ventricle is the harder one to recreate given its higher operating pressures, and we like to start with the hard challenges,” Roche says.

The heart, unfurled

The heart normally pumps blood by squeezing and twisting, a complex combination of motions that is a result of the alignment of muscle fibers along the outer myocardium that covers each of the heart’s ventricles. The team planned to fabricate a matrix of artificial muscles resembling inflatable bubbles, aligned in the orientations of the natural cardiac muscle. But copying these patterns by studying a ventricle’s three-dimensional geometry proved extremely challenging.

They eventually came across the helical ventricular myocardial band theory, the idea that cardiac muscle is essentially a large helical band that wraps around each of the heart’s ventricles. This theory is still a subject of debate by some researchers, but Roche and her colleagues took it as inspiration for their design. Instead of trying to copy the left ventricle’s muscle fiber orientation from a 3D perspective, the team decided to remove the ventricle’s outer muscle tissue and unwrap it to form a long, flat band — a geometry that should be far easier to recreate. In this case, they used the cardiac tissue from an explanted pig heart.

In collaboration with co-lead author Chris Nguyen at MGH, the researchers used diffusion tensor imaging, an advanced technique that typically tracks how water flows through white matter in the brain, to map the microscopic fiber orientations of a left ventricle’s unfurled, two-dimensional muscle band. They then fabricated a matrix of artificial muscle fibers made from thin air tubes, each connected to a series of inflatable pockets, or bubbles, the orientation of which they patterned after the imaged muscle fibers.

Motion of the biorobotic hybrid heart mimics the pumping motion of the heart under echocardiography. Credit: Mossab Saeed

The soft matrix consists of two layers of silicone, with a water-soluble layer between them to prevent the layers from sticking, as well as two layers of laser-cut paper, which ensures that the bubbles inflate in a specific orientation.

The researchers also developed a new type of bioadhesive to glue the bubble wrap to the ventricle’s real, intracardiac tissue. While adhesives exist for bonding biological tissues to each other, and and for materials like silicone to each other, the team  realized few soft adhesives do an adequate job of gluing together biological tissue with synthetic materials, silicone in particular.

So Roche collaborated with Zhao, associate professor of mechanical engineering at MIT, who specializes in developing hydrogel-based adhesives. The new adhesive, named TissueSil, was made by functionalizing silicone in a chemical cross-linking process, to bond with components in heart tissue. The result was a viscous liquid that the researchers brushed onto the soft robotic matrix. They also brushed the glue onto a new explanted pig heart that had its left ventricle removed but its endocardial structures preserved. When they wrapped the artificial muscle matrix around this tissue, the two bonded tightly.

Finally, the researchers placed the entire hybrid heart in a mold that they had previously cast of the original, whole heart, and filled the mold with silicone to encase the hybrid heart in a uniform covering — a step that produced a form similar to a real heart and ensured that the robotic bubble wrap fit snugly around the real ventricle.

“That way, you don’t lose transmission of motion from the synthetic muscle to the biological tissue,” Roche says.

When the researchers pumped air into the bubble wrap at frequencies resembling a naturally beating heart, and imaged the bionic heart’s response, it contracted in a manner similar to the way a real heart moves to pump blood through the body.

Ultimately, the researchers hope to use the bionic heart as a realistic environment to help designers test cardiac devices such as prosthetic heart valves.

“Imagine that a patient before cardiac device implantation could have their heart scanned, and then clinicians could tune the device to perform optimally in the patient well before the surgery,” says Nyugen. “Also, with further tissue engineering, we could potentially see the biorobotic hybrid heart be used as an artificial heart — a very needed potential solution given the global heart failure epidemic where millions of people are at the mercy of a competitive heart transplant list.”

This research was supported in part by the National Science Foundation.

Topics:Bioengineering and biotechnologyMedicineHealth sciences and technologyCivil and environmental engineeringInstitute for Medical Engineering and Science (IMES)Mechanical engineeringResearchRoboticsSchool of EngineeringSchool of ScienceNational Science Foundation (NSF)



About This Website

This Website is maintained by the MIT News Office, part of the Office of Communications.


GIVE TO MITMassachusetts Institute of Technology

MIT News Office • Building 11-400
Massachusetts Institute of Technology • Cambridge, MA 02139-4307

Artificial heart

From Wikipedia, the free encyclopediaJump to navigationJump to searchThis article is about the mechanical device. For the Jonathan Coulton album, see Artificial Heart (album).

Artificial heart
An artificial heart displayed at the London Science Museum
[edit on Wikidata]

An artificial heart is a device that replaces the heart. Artificial hearts are typically used to bridge the time to heart transplantation, or to permanently replace the heart in case heart transplantation is impossible. Although other similar inventions preceded it from the late 1940s, the first artificial heart to be successfully implanted in a human was the Jarvik-7 in 1982, designed by a team including Willem Johan Kolff and Robert Jarvik.

An artificial heart is distinct from a ventricular assist device (VAD) designed to support a failing heart. It is also distinct from a cardiopulmonary bypass machine, which is an external device used to provide the functions of both the heart and lungs, used only for a few hours at a time, most commonly during cardiac surgery.



The SynCardia temporary Total Artificial Heart

 This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: “Artificial heart” – news · newspapers · books · scholar · JSTOR (April 2018) (Learn how and when to remove this template message)


A synthetic replacement for the heart remains a long-sought “holy grail” of modern medicine. The obvious benefit of a functional artificial heart would be to lower the need for heart transplants, because the demand for organs always greatly exceeds supply.

Although the heart is conceptually a pump, it embodies subtleties that defy straightforward emulation with synthetic materials and power supplies. Consequences of these issues include severe foreign-body rejection and external batteries that limit mobility. These complications limited the lifespan of early human recipients to hours or days.

Early development[edit]

The first artificial heart was made by the Soviet scientist Vladimir Demikhov in 1937. It was implanted in a dog.

On 2 July 1952, 41-year-old Henry Opitek, suffering from shortness of breath, made medical history at Harper University Hospital at Wayne State University in Michigan. The Dodrill-GMR heart machine, considered to be the first operational mechanical heart, was successfully used while performing heart surgery.[1][2] Ongoing research was done on calves at Hershey Medical Center, Animal Research Facility, in Hershey, Pennsylvania, during the 1970s.

Forest Dewey Dodrill, working closely with Matthew Dudley, used the machine in 1952 to bypass Henry Opitek’s left ventricle for 50 minutes while he opened the patient’s left atrium and worked to repair the mitral valve. In Dodrill’s post-operative report, he notes, “To our knowledge, this is the first instance of survival of a patient when a mechanicaly heart mechanism was used to take over the complete body function of maintaining the blood supply of the body while the heart was open and operated on.”[3]

heart–lung machine was first used in 1953 during a successful open heart surgery. John Heysham Gibbon, the inventor of the machine, performed the operation and developed the heart–lung substitute himself.

Following these advances, scientific interest for the development of a solution for heart disease developed in numerous research groups worldwide.

Early designs of total artificial hearts[edit]

In 1949, a precursor to the modern artificial heart pump was built by doctors William Sewell and William Glenn of the Yale School of Medicine using an Erector Set, assorted odds and ends, and dime-store toys. The external pump successfully bypassed the heart of a dog for more than an hour.[4]

Paul Winchell invented an artificial heart with the assistance of Henry Heimlich (the inventor of the Heimlich maneuver) and held the first patent for such a device. The University of Utah developed a similar apparatus around the same time, but when they tried to patent it, Winchell’s heart was cited as prior art. The university requested that Winchell donate the heart to the University of Utah, which he did. There is some debate as to how much of Winchell’s design Robert Jarvik used in creating Jarvik’s artificial heart. Heimlich states, “I saw the heart, I saw the patent and I saw the letters. The basic principle used in Winchell’s heart and Jarvik’s heart is exactly the same.[5]” Jarvik denies that any of Winchell’s design elements were incorporated into the device he fabricated for humans which was successfully implanted into Barney Clark in 1982.

On 12 December 1957, Willem Johan Kolff, the world’s most prolific inventor of artificial organs, implanted an artificial heart into a dog at Cleveland Clinic. The dog lived for 90 minutes.

In 1958, Domingo Liotta initiated the studies of TAH replacement at Lyon, France, and in 1959–60 at the National University of Córdoba, Argentina. He presented his work at the meeting of the American Society for Artificial Internal Organs held in Atlantic City in March 1961. At that meeting, Liotta described the implantation of three types of orthotopic (inside the pericardial sac) TAHs in dogs, each of which used a different source of external energy: an implantable electric motor, an implantable rotating pump with an external electric motor, and a pneumatic pump.[6][7]

In 1964, the National Institutes of Health started the Artificial Heart Program, with the goal of putting an artificial heart into a human by the end of the decade.[8] The purpose of the program was to develop an implantable artificial heart, including the power source, to replace a failing heart.[9]

In February 1966, Adrian Kantrowitz rose to international prominence when he performed the world’s first permanent implantation of a partial mechanical heart (left ventricular assist device) at Maimonides Medical Center.[10]

In 1967, Kolff left Cleveland Clinic to start the Division of Artificial Organs at the University of Utah and pursue his work on the artificial heart.

  1. In 1973, a calf named Tony survived for 30 days on an early Kolff heart.
  2. In 1975, a bull named Burk survived 90 days on the artificial heart.
  3. In 1976, a calf named Abebe lived for 184 days on the Jarvik 5 artificial heart.
  4. In 1981, a calf named Alfred Lord Tennyson lived for 268 days on the Jarvik 5.

Over the years, more than 200 physicians, engineers, students and faculty developed, tested and improved Kolff’s artificial heart. To help manage his many endeavors, Kolff assigned project managers. Each project was named after its manager. Graduate student Robert Jarvik was the project manager for the artificial heart, which was subsequently renamed the Jarvik 7.

In 1981, William DeVries submitted a request to the FDA for permission to implant the Jarvik 7 into a human being. On 2 December 1982, Kolff implanted the Jarvik 7 artificial heart into Barney Clark, a dentist from Seattle who was suffering from severe congestive heart failure. Clark lived for 112 days tethered to an external pneumatic compressor, a device weighing some 400 pounds (180 kg), but during that time he suffered prolonged periods of confusion and a number of instances of bleeding, and asked several times to be allowed to die.[11]

First clinical implantation of a total artificial heart[edit]

On 4 April 1969, Domingo Liotta and Denton A. Cooley replaced a dying man’s heart with a mechanical heart inside the chest at The Texas Heart Institute in Houston as a bridge for a transplant. The man woke up and began to recover. After 64 hours, the pneumatic-powered artificial heart was removed and replaced by a donor heart. However thirty-two hours after transplantation, the man died of what was later proved to be an acute pulmonary infection, extended to both lungs, caused by fungi, most likely caused by an immunosuppressive drug complication.[12]

The original prototype of Liotta-Cooley artificial heart used in this historic operation is prominently displayed in the Smithsonian Institution‘s National Museum of American History “Treasures of American History” exhibit in Washington, D.C.[13]

First clinical applications of a permanent pneumatic total artificial heart[edit]

The first clinical use of an artificial heart designed for permanent implantation rather than a bridge to transplant occurred in 1982 at the University of Utah. Artificial kidney pioneer Willem Johan Kolff started the Utah artificial organs program in 1967.[14] There, physician-engineer Clifford Kwan-Gett invented two components of an integrated pneumatic artificial heart system: a ventricle with hemispherical diaphragms that did not crush red blood cells (a problem with previous artificial hearts) and an external heart driver that inherently regulated blood flow without needing complex control systems.[15] Independently, Paul Winchell designed and patented a similarly shaped ventricle and donated the patent to the Utah program.[16] Throughout the 1970s and early 1980s, veterinarian Donald Olsen led a series of calf experiments that refined the artificial heart and its surgical care. During that time, as a student at the University of Utah, Robert Jarvik combined several modifications: an ovoid shape to fit inside the human chest, a more blood-compatible polyurethane developed by biomedical engineer Donald Lyman, and a fabrication method by Kwan-Gett that made the inside of the ventricles smooth and seamless to reduce dangerous stroke-causing blood clots.[17] On 2 December 1982, William DeVries implanted the artificial heart into retired dentist Barney Bailey Clark (born 21 January 1921), who survived 112 days with the device, dying on 23 March 1983. Bill Schroeder became the second recipient and lived for a record 620 days.

Contrary to popular belief and erroneous articles in several periodicals, the Jarvik heart was not banned for permanent use. Today, the modern version of the Jarvik 7 is known as the SynCardia temporary Total Artificial Heart. It has been implanted in more than 1,350 people as a bridge to transplantation.

In the mid-1980s, artificial hearts were powered by dishwasher-sized pneumatic power sources whose lineage went back to Alfa Laval milking machines. Moreover, two sizable catheters had to cross the body wall to carry the pneumatic pulses to the implanted heart, greatly increasing the risk of infection. To speed development of a new generation of technologies, the National Heart, Lung, and Blood Institute opened a competition for implantable electrically powered artificial hearts. Three groups received funding: Cleveland Clinic in Cleveland, Ohio; the College of Medicine of Pennsylvania State University (Penn State Hershey Medical Center) in Hershey, Pennsylvania; and AbioMed, Inc. of Danvers, Massachusetts. Despite considerable progress, the Cleveland program was discontinued after the first five years.

First clinical application of an intrathoracic pump[edit]

On 19 July 1963, E. Stanley Crawford and Domingo Liotta implanted the first clinical Left Ventricular Assist Device (LVAD) at The Methodist Hospital in Houston, Texas, in a patient who had a cardiac arrest after surgery. The patient survived for four days under mechanical support but did not recover from the complications of the cardiac arrest; finally, the pump was discontinued, and the patient died.

First clinical application of a paracorporeal pump[edit]

1966 DeBakey ventricular assist device.[18]

On 21 April 1966, Michael DeBakey and Liotta implanted the first clinical LVAD in a paracorporeal position (where the external pump rests at the side of the patient) at The Methodist Hospital in Houston, in a patient experiencing cardiogenic shock after heart surgery. The patient developed neurological and pulmonary complications and died after few days of LVAD mechanical support. In October 1966, DeBakey and Liotta implanted the paracorporeal Liotta-DeBakey LVAD in a new patient who recovered well and was discharged from the hospital after 10 days of mechanical support, thus constituting the first successful use of an LVAD for postcardiotomy shock.

First VAD patient with FDA approved hospital discharge[edit]

In 1990 Brian Williams was discharged from the University of Pittsburgh Medical Center (UPMC), becoming the first VAD patient to be discharged with Food and Drug Administration (FDA) approval.[19] The patient was supported in part by bioengineers from the University of Pittsburgh’s McGowan Institute.[19][20]

Total artificial heart prototypes[edit]

Total artificial heart pump[edit]

The U.S. Army artificial heart pump was a compact, air-powered unit developed by Dr. Kenneth Woodward at Harry Diamond Laboratories in the early to mid-1960s.[21][22] The Army’s heart pump was partially made of Lucite, also called Plexiglass, and consisted of two valves, a chamber, and a suction flapper.[21] The pump operated without any moving parts under the principle of fluid amplification – providing a pulsating air pressure source resembling a heartbeat.[22] Harry Diamond Laboratories was later merged with Army Research Laboratory in 1992.[23]


Since 1991, the Foundation for Cardiac Surgery Development (FRK) in Zabrze, Poland has been working on developing an artificial heart. Nowadays, the Polish system for heart support POLCAS consists of the artificial ventricle POLVAD-MEV and the three controllers POLPDU-401, POLPDU-402 and POLPDU-501. Presented devices are designed to handle only one patient. The control units of the 401 and 402 series may be used only in hospital due to its big size, method of control and type of power supply. The control[24] unit of 501 series is the latest product of FRK. Due to its much smaller size and weight, it is significantly more mobile solution. For this reason, it can be also used during supervised treatment conducted outside the hospital.


In June 1996, a 46-year-old man received a total artificial heart implantation done by Jeng Wei at Cheng-Hsin General Hospital[25] in the Republic of China (Taiwan). This technologically advanced pneumatic Phoenix-7 Total Artificial Heart was manufactured by a Taiwanese dentist Kelvin K. Cheng, a Chinese physician T. M. Kao and colleagues at the Taiwan TAH Research Center in TainanRepublic of China (Taiwan). With this experimental artificial heart, the patient’s BP was maintained at 90-100/40-55 mmHg and cardiac output at 4.2–5.8 L/min.[26] The patient then received the world’s first successful combined heart and kidney transplantation after bridging with a total artificial heart.[27]

Abiomed AbioCor[edit]

The first AbioCor to be surgically implanted in a patient was on 3 July 2001. [28] The AbioCor is made of titanium and plastic with a weight of 0,9 kg (two pounds), and its internal battery can be recharged with a transduction device that sends power through the skin.[28] The internal battery lasts for half an hour, and a wearable external battery pack lasts for four hours.[29] The FDA announced on 5 September 2006, that the AbioCor could be implanted for humanitarian uses after the device had been tested on 15 patients.[30] It is intended for critically ill patients who cannot receive a heart transplant.[30] Some limitations of the current AbioCor are that its size makes it suitable for less than 50% of the female population and only about 50% of the male population, and its useful life is only 1–2 years.[31]

After a great deal of experimentation, AbioMed abandoned development of the product in 2015.[32] The company currently markets the Impella Ventricular Support Systems, pumps “intended to help pump blood in patients who need short-term support (up to 6 days)”.[33]


SynCardia is a company based in Tucson, Arizona which currently has two separate models available. It is available in a 70cc and 50cc size. The 70 cc is used for biventricular heart failure in adult men, while the 50cc is for children and women.[34] As good results with the TAH as a bridge to heart transplant accumulated, a trial of the CardioWest TAH (developed from the Jarvik 7 and now marketed as the Syncardia TAH) was initiated in 1993 and completed in 2002.[35] As of 2014, more than 1,250 patients have received SynCardia artificial hearts.[36][37][36] The device requires the use of the Companion 2 hospital driver or the Freedom portable driver to power the heart with pulses of air. The drivers also monitor blood flow for each ventricle.[38]

In 2016, Syncardia filed for bankruptcy protection and was later acquired by the private equity firm Versa Capital Management.[39]

A January 2019 report in Europe stated that “there is only one fully artificial heart currently in the market, developed by US-based SynCardia”.[40]


Another U.S. team has a prototype called the 2005 MagScrew Total Artificial Heart. Teams in Japan and South Korea are also racing to produce similar devices.[41][42][43][44]

Cleveland Heart[edit]

The Cleveland Heart is a continuous-flow total artificial heart (CFTAH)[citation needed]

Abiomed AbioCor II[edit]

By combining its valved ventricles with the control technology and roller screw developed at Penn State, AbioMed has designed a smaller, more stable heart, the AbioCor II. This pump, which should be implantable in most men and 50% of women with a life span of up to five years,[31] had animal trials in 2005, and the company hoped to get FDA approval for human use in 2008.[45] In 2019, this product was not being marketed; instead, Abiomed was marketing the Impella series of heart pumps.[46]

Carmat bioprosthetic heart[edit]

Carmat’s artificial heart.

On 27 October 2008, French professor and leading heart transplant specialist Alain F. Carpentier announced that a fully implantable artificial heart would be ready for clinical trial by 2011 and for alternative transplant in 2013. It was developed and would be manufactured by him, biomedical firm CARMAT SA,[47] and venture capital firm Truffle Capital. The prototype used embedded electronic sensors and was made from chemically treated animal tissues, called “biomaterials”, or a “pseudo-skin” of biosyntheticmicroporous materials.[48]

According to a press-release by Carmat dated 20 December 2013, the first implantation of its artificial heart in a 75-year-old patient was performed on 18 December 2013 by the Georges Pompidou European Hospital team in Paris (France).[49] The patient died 75 days after the operation.[50]

In Carmat’s design, two chambers are each divided by a membrane that holds hydraulic fluid on one side. A motorized pump moves hydraulic fluid in and out of the chambers, and that fluid causes the membrane to move; blood flows through the other side of each membrane. The blood-facing side of the membrane is made of tissue obtained from a sac that surrounds a cow’s heart, to make the device more biocompatible. The Carmat device also uses valves made from cow heart tissue and has sensors to detect increased pressure within the device. That information is sent to an internal control system that can adjust the flow rate in response to increased demand, such as when a patient is exercising.[51] This distinguishes it from previous designs that maintain a constant flow rate.

The Carmat device, unlike previous designs, is meant to be used in cases of terminal heart failure, instead of being used as a bridge device while the patient awaits a transplant.[52] At 900 grams it weighs nearly three times the typical heart and is targeted primarily towards obese men. It also requires the patient to carry around an additional Li-Ion battery. The projected lifetime of the artificial heart is around 5 years (230 million beats).[53]

In 2016, trials for the Carmat “fully artificial heart” were banned by the National Agency for Security and Medicine in Europe after short survival rates were confirmed. The ban was lifted in May 2017. At that time, a European report stated that Celyad’s C-Cure cell therapy for ischemic heart failure[54][54] “could only help a subpopulation of Phase III study participants, and Carmat will hope that its artificial heart will be able to treat a higher proportion of heart failure patients”.[55]

A January 2019 update in Europe stated that the only fully artificial heart currently in the market was the SynCardia device and that Carmat’s artificial heart (“designed to self-regulate, changing the blood flow based on the patient’s physical activity”) was still in the early stage of trials. That report also indicated that Carmat was, in fact, still hoping to “gain market approval for its implant this year, but is now aiming to achieve this next year. One reason for this is that the complex technology has been undergoing refinements in the manufacturing process”.[40]


On 12 March 2011, an experimental artificial heart was implanted in 55-year-old Craig Lewis at The Texas Heart Institute in Houston by O. H. Frazier and William Cohn. The device is a combination of two modified HeartMate II pumps that is currently undergoing bovine trials.[56]

Frazier and Cohn are on the board of the BiVACOR company that develops an artificial heart.[57][58] BiVACOR has been tested as a replacement for a heart in a sheep.[59][60]

So far, only one person has benefited from Frazier and Cohn’s artificial heart. Craig Lewis was suffering from amyloidosis in 2011 when his heart gave out and doctors pronounced that he had only 12 to 24 hours to live. After obtaining permission from his family, Frazier and Cohn replaced his heart with their device. Lewis survived for another 5 weeks after the operation; he eventually succumbed to liver and kidney failure due to his amyloidosis, after which his family asked that his artificial heart be unplugged.[61]Soft Total Artificial Heart, developed in the functional material laboratory at ETH Zürich

Soft artificial heart[edit]

On 10 July 2017, Nicholas Cohrs and colleagues presented a new concept of a soft total artificial heart in the Journal of Artificial Organs.[62] The heart was developed in the Functionals Materials Laboratory at ETH Zurich.[63] (Cohrs was listed as a doctoral student in a group led by Professor Wendelin Stark at ETH Zurich.)[64]

The soft artificial heart (SAH) was created from silicone with the help of 3D printing technology. The SAH is a silicone monoblock. It weighs 390g, has a volume of 679 cm3 and is operated through pressurized air. “Our goal is to develop an artificial heart that is roughly the same size as the patient’s own one and which imitates the human heart as closely as possible in form and function” says Cohrs in an interview.[65] The SAH fundamentally moves and works like a real heart but currently only beats for 3000 beats[66] in a hybrid mock circulation machine.[67]

The working life of a more recent Cohrs prototype (using various polymers instead of silicone)[67] was still limited, according to reports in early 2018, with that model providing a useful life of 1 million heartbeats, roughly ten days in a human body.[68] At the time, Cohrs and his team were experimenting with CAD software and 3D printing, striving to develop a model that would last up to 15 years. “We cannot really predict when we could have a final working heart which fulfills all requirements and is ready for implantation. This usually takes years”, said Cohrs.[69]


centrifugal pump[70][71] or an axial-flow pump[72][73] can be used as an artificial heart, resulting in the patient being alive without a pulse.

A centrifugal artificial heart which alternately pumps the pulmonary circulation and the systemic circulation, causing a pulse, has been described.[74]

Researchers have constructed a heart out of foam. The heart is made out of flexible silicone and works with an external pump to push air and fluids through the heart. It currently cannot be implanted into humans, but it is a promising start for artificial hearts.[75]

Hybrid assistive devices[edit]

Main article: Ventricular assist device

Patients who have some remaining heart function but who can no longer live normally may be candidates for ventricular assist devices (VAD), which do not replace the human heart but complement it by taking up much of the function.

The first Left Ventricular Assist Device (LVAD) system was created by Domingo Liotta at Baylor College of Medicine in Houston in 1962.[76]

Another VAD, the Kantrowitz CardioVad, designed by Adrian Kantrowitz boosts the native heart by taking up over 50% of its function.[77] Additionally, the VAD can help patients on the wait list for a heart transplant. In a young person, this device could delay the need for a transplant by 10–15 years, or even allow the heart to recover, in which case the VAD can be removed.[77] The artificial heart is powered by a battery that needs to be changed several times while still working.

The first heart assist device was approved by the FDA in 1994, and two more received approval in 1998.[78] While the original assist devices emulated the pulsating heart, newer versions, such as the Heartmate II,[79] developed by The Texas Heart Institute of Houston, provide continuous flow. These pumps (which may be centrifugal or axial flow) are smaller and potentially more durable and last longer than the current generation of total heart replacement pumps. Another major advantage of a VAD is that the patient keeps the natural heart, which may still function for temporary back-up support if the mechanical pump were to stop. This may provide enough support to keep the patient alive until a solution to the problem is implemented.

In August 2006, an artificial heart was implanted into a 15-year-old girl at the Stollery Children’s Hospital in EdmontonAlberta. It was intended to act as a temporary fixture until a donor heart could be found. Instead, the artificial heart (called a Berlin Heart) allowed for natural processes to occur and her heart healed on its own. After 146 days, the Berlin Heart was removed, and the girl’s heart functioned properly on its own.[80] On 16 December 2011 the Berlin Heart gained U.S. FDA approval. The device has since been successfully implanted in several children including a 4-year-old Honduran girl at Children’s Hospital Boston.[81]

Several continuous-flow ventricular assist devices have been approved for use in the European Union, and, as of August 2007, were undergoing clinical trials for FDA approval.

In 2012, a study published in the New England Journal of Medicine compared the Berlin Heart to extracorporeal membrane oxygenation (ECMO) and concluded that “a ventricular assist device available in several sizes for use in children as a bridge to heart transplantation [such as the Berlin Heart] was associated with a significantly higher rate of survival as compared with ECMO.”[82] The study’s primary author, Charles D. Fraser, Jr., surgeon in chief at Texas Children’s Hospital, explained: “With the Berlin Heart, we have a more effective therapy to offer patients earlier in the management of their heart failure. When we sit with parents, we have real data to offer so they can make an informed decision. This is a giant step forward.”[83]

Suffering from end-stage heart failure, former Vice President Dick Cheney underwent a procedure in July 2010 to have a VAD implanted at INOVA Fairfax Hospital, in Fairfax Virginia. In 2012, he received a heart transplant at age 71 after 20 months on a waiting list.

See also[edit]


General references[edit]

Inline citations[edit]

  1. ^ “The Mechanical Heart celebrates 50 lifesaving years”. American Heart Association. 9 February 2008. Archived from the original on 21 November 2010. Retrieved 8 March 2013. and “Mechanical Heart Celebrates 50 Lifesaving Years”Archivedfrom the original on 19 August 2016. Retrieved 3 June 2015..
  2. ^ “50th Anniversary of First Open Heart Surgery – Newsroom”. 13 February 2018. Archived from the original on 1 May 2015.
  3. ^ Stephenson Larry W; et al. (2002). “The Michigan Heart: The World’s First Successful Open Heart Operation?”. Journal of Cardiac Surgery17 (3): 238–246. doi:10.1111/j.1540-8191.2002.tb01209.xPMID 12489911.
  4. ^ Lavietes, Stuart. William Glenn, 88, Surgeon Who Invented Heart Procedure Archived 2017-08-10 at the Wayback MachineThe New York Times, 17 March 2003. Accessed 21 May 2009.
  5. ^ “jarvik7.jpg (625×800 pixels)” 18 August 2016. Archived from the original on 18 August 2016.
  6. ^ “Artificial Heart in the chest: Preliminary report”. Trans. Amer. Soc. Inter. Organs7: 318. 1961.
  7. ^ “Ablation experimentale et replacement du coeur par un coer artificial intra-thoracique”. Lyon Cirurgical57: 704. 1961.
  8. ^ Sandeep Jauhar: The Artificial Heart. New England Journal of Medicine (2004): 542–544.
  9. ^ Hwang, Ned H. C.; Woo, Savio L.-Y. (31 December 2003). Frontiers in Biomedical Engineering: Proceedings of the World Congress for Chinese Biomedical Engineers. Springer Science & Business Media. ISBN 9780306477164 – via Google Books.
  10. ^ Cooley, D. A. (2009). “In Memoriam: Adrian Kantrowitz 1918–2008”Texas Heart Institute Journal36 (1): 1–3. PMC 2676518.
  11. ^ Barron H. Lerner, MD (1 December 2007). “The 25th Anniversary of Barney Clark’s Artificial Heart”Celebrity Health. Archived from the original on 29 June 2011. Retrieved 15 November 2010.
  12. ^ Orthotopic cardiac prosthesis for two-staged cardiac replacement. Am J Cardio 1969; 24:723–730.
  13. ^ “Treasures of American History” Archived 2011-06-29 at Wikiwix, National Museum of American History
  14. ^ Spare Parts: Organ Replacement in American Society. Renee C. Fox and Judith P. Swazey. New York: Oxford University Press; 1992, pp. 102–104
  15. ^ Kwan-Gett CS, Van Kampen KR, Kawai J, Eastwood N, Kolff WJ (December 1971). “Results of total artificial heart implantation in calves”. Journal of Thoracic and Cardiovascular Surgery62 (6): 880–889.
  16. ^ “Winchell’s Heart”Time. 12 March 1973. Archived from the original on 6 September 2010. Retrieved 25 April 2010.
  17. ^ “Kolff”Archived from the original on 7 October 2008.
  18. ^ “Dr. Denton Cooley and Dr. Michael E. DeBakey: Rock stars of Houston medicine”Houston Chronicle. 3 April 2014. Archivedfrom the original on 14 March 2015. Retrieved 7 March 2015.
  19. Jump up to:a b “Revolutionizing Care for Failing Hearts – William G. McGowan Charitable Fund”. Archived from the original on 13 May 2016. Retrieved 27 April 2016.
  20. ^ “Pittsburgh’s 25th Anniversary of First VAD Patient to Be Discharged from a Hospital – Regenerative Medicine at the McGowan Institute”Archived from the original on 29 June 2016.
  21. Jump up to:a b McKellar, Shelley (3 January 2018). Artificial Hearts: The Allure and Ambivalence of a Controversial Medical Technology. JHU Press. ISBN 9781421423555.
  22. Jump up to:a b Mechanical Devices to Assist the Failing Heart: Proceedings. National Academies. 1966.
  23. ^ “Wayback Machine” (PDF). 12 November 2008. Archived from the original (PDF) on 12 November 2008. Retrieved 30 July2018.
  24. ^ Fajdek, Bartlomiej; Janiszowski, Krzysztof (2014). Automatic control system for ventricular assist device. pp. 874–879. doi:10.1109/MMAR.2014.6957472ISBN 978-1-4799-5081-2.
  25. ^ “Cheng-Hsin General Hospital”. Archived from the originalon 1 February 2015.
  26. ^ Hsu, Cheung-HWA (2001). “In Vivo and Clinical Study of Phoenix-7 Total Artificial Heart”Biomedical Engineering: Applications, Basis and Communications13 (3): 133–139. doi:10.4015/S1016237201000170.
  27. ^ Wei J.; Cheng K. K.; Tung D. Y.; Chang C. Y.; Wan W. M.; Chuang Y. C. (1998). “Successful Use of Phoenix-7 Total Artificial Heart”. Transplantation Proceedings30 (7): 3403–4. doi:10.1016/s0041-1345(98)01078-1PMID 9838499.
  28. Jump up to:a b “Patient gets first totally implanted artificial heart”. 3 July 2001. Archived from the original on 7 June 2008. Retrieved 13 July 2008.
  29. ^ “AbioCor FAQs”. AbioMed. Archived from the original on 3 July 2008. Retrieved 13 July 2008.
  30. Jump up to:a b “FDA Approves First Totally Implanted Permanent Artificial Heart for Humanitarian Uses”. 5 September 2006. Archived from the original on 8 October 2008. Retrieved 13 July2008.
  31. Jump up to:a b “Will We Merge With Machines?”. 1 August 2005. Archived from the original on 19 July 2008. Retrieved 13 July 2008.
  32. ^ Leprince, P. (6 October 2015). “Total artificial heart: What’s new?” (PDF). Daily News – EACTS. European Association for Cardio-Thoracic Surgery. p. 7. Archived from the original (PDF)on 15 March 2016. Retrieved 15 March 2016.
  33. ^ Health, Center for Devices Radiological (3 June 2019). “Impella Ventricular Support Systems – P140003/S018”FDA.
  34. ^ “Two Sizes Intended to Treat Most Patients”SynCardia. 16 November 2015. Archived from the original on 17 November 2015.
  35. ^ Copeland JG, Smith RG, Arabia FA, et al. (2004). “Cardiac replacement with a total artificial heart as a bridge to transplantation”. N Engl J Med351 (9): 859–67. doi:10.1056/nejmoa040186PMID 15329423.
  36. Jump up to:a b “New Record of 161 SynCardia Total Artificial Heart Implants Set In 2013”SynCardia. 7 January 2014. Archived from the original on 13 January 2016. Retrieved 11 June 2016.
  37. ^ Torregrossa G, Morshuis M, Varghese R, et al. (2014). “Results with SynCardia total artificial heart beyond 1 year”. ASAIO J60(6): 626–34. doi:10.1097/MAT.0000000000000132PMID 25158888. One patient had the artificial heart for 1,374 days, that is, nearly four years.
  38. ^ “UCLA Transplantation Services, Los Angeles, CA”transplants.ucla.eduArchived from the original on 6 August 2016.
  39. ^ “Carmat’s heart sinks with another delay”. 15 January 2019.
  40. Jump up to:a b “Artificial Heart Offers Hope to Heart Failure Patients”. 16 January 2019.
  41. ^ Weber S, Kamohara K, Klatte RS, Luangphakdy V, Flick C, Chen JF, Casas F, Ootaki Y, Kopcak M, Akiyama M, Hirschman GB, Chapman PA, Donahue A, Wetterau W, Prisco C, Mast R, Sherman C, Fukamachi K, Smith WA (2005). “MagScrew TAH: an update”. ASAIO J51 (6): xxxvi–xlvi. doi:10.1097/01.mat.0000187395.29817.36PMID 16340348.
  42. ^ “Japanese Researchers Advance Artificial Heart Design” 15 December 2014. Archived from the original on 6 October 2016. Retrieved 18 August 2016.
  43. ^ “Artificial heart” from the original on 22 August 2016.
  44. ^ Min, B. G.; Kim, H. C.; Choi, J. W.; Ryu, G. H.; Seo, K. P.; Rho, J. R.; Ahn, H.; Kim, S. W.; Diegel, P. D.; Olsen, D. B. (December 1990). “A moving-actuator type electromechanical total artificial heart. II. Circular type and animal experiment”. IEEE Transactions on Biomedical Engineering37 (12): 1195–1200. doi:10.1109/10.64462PMID 2289793.
  45. ^ “14th Artificial Heart Patient Dies: A Newsmaker Interview With Robert Kung, PhD”. 11 November 2004. Archived from the original on 25 April 2013. Retrieved 13 July2008.
  46. ^ “ABIOMED | Impella®”.
  47. ^ atorsoli, Albertina Torsoli. “A Synthetic Heart That Keeps on Ticking”Archived from the original on 6 August 2016.
  48. ^ “The Carmat Heart,- The technology behind the prosthesis”. Archived from the original on 29 June 2013.
  49. ^ “First-in-man implantation of CARMAT’s bioprosthetic artificial heart”. Archived from the original on 24 December 2013.
  50. ^ “First patient fitted with Carmat artificial heart dies”Reuters. 3 March 2014. Archived from the original on 30 September 2015.
  51. ^ Rojahn, Susan Young. “Biology and Machine Come Together in a New Artificial Heart”.
  52. ^ “Carmat artificial heart patient in good condition: hospital”Reuters. 30 December 2013. Archived from the original on 24 September 2015.
  53. ^ Polska, Wirtualna. “Pierwsze wszczepione na stałe sztuczne serce bije już w ludzkiej piersi –”. Archived from the original on 30 December 2013. Retrieved 27 December2013.
  54. Jump up to:a b “Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy”. 11 May 2017.
  55. ^ “Implantation of Carmat’s Artificial Heart Begins in Denmark to Beat Low Enrolment”. 21 February 2018.
  56. ^ Berger, Eric. “New artificial heart ‘a leap forward'”Houston ChronicleArchived from the original on 26 March 2011. Retrieved 23 March 2011.
  57. ^ “Donor brings inventor of artificial heart closer to Houston”Houston Chronicle. 14 January 2013. Archived from the original on 25 September 2015.
  58. ^ “Living without a pulse: Engineering a better artificial heart”CNN. 4 December 2013. Archived from the original on 9 April 2014.
  59. ^ “BiVACOR beatless artificial heart appeal hopes to raise $5 million”Courier Mail. 7 March 2015.
  60. ^ “Bionic heart breakthrough: Scientists transplant device into sheep, hope for clinical trials”ABC News. Australian Broadcasting Corporation. 7 March 2015. Archived from the original on 9 March 2015.
  61. ^ “Walking Dead – The First Human Able to Survive Without a Heart OR a Pulse”Bam Marguera. Archived from the originalon 5 April 2015. Retrieved 4 April 2015.
  62. ^ Cohrs Nicholas H (2017). “A Soft Total Artificial Heart-First Concept Evaluation on a Hybrid Mock Circulation”. Artificial Organs41 (10): 948–958. doi:10.1111/aor.12956PMID 28691283.
  63. ^ “Our work on soft artificial hearts highlighted in the media”http://www.fml.ethz.chArchived from the original on 5 August 2017.
  64. ^ “This 3-D-printed artificial heart actually beats”. CNN. 20 July 2017. Retrieved 12 March 2019. Wendelin Stark, a professor of functional materials engineering at the Swiss science and technology university, made the pulsing heart, along with his doctoral student Nicholas Cohrs and other researchers, using a wax casting technique.
  65. ^ “Testing a soft artificial heart”http://www.ethz.chArchived from the original on 21 July 2017.
  66. ^ ETH Zürich (12 July 2017). “Testing a soft artificial heart”Archived from the original on 21 July 2017 – via YouTube.
  67. Jump up to:a b “Scientists Developing Softer, Longer Lasting Artificial Heart”. Healthline. 6 January 2018. Retrieved 12 March 2019.
  68. ^ “Scientists Developing Softer, Longer Lasting Artificial Heart”. CNBC. 2 March 2018. Retrieved 12 March 2019. The Swiss group published the results in the journal Artificial Organs last year. The heart lasted for 3,000 beats, or about 30 minutes, before rupturing. “It always ruptured at the same position,” Cohrs said. They are currently working on a new prototype with optimized geometry to fix the structural issues, as well as with a new, sturdier material. In the latest test, the new prototype lasted for 1 million beats before they stopped the experiment.
  69. ^ “Scientists Developing Softer, Longer Lasting Artificial Heart”. Healthline. 6 January 2018. Retrieved 12 March 2019. Our ultimate goal would of course be a soft artificial heart which can produce a physiological, natural blood flow, has a sufficient lifetime, and does not cause adverse events,” Cohrs said. “Whether this is possible is still unknown, but we were happy with the first results.
  70. ^ Black, Rosemary (5 January 2011). “Former vice president Dick Cheney now has no pulse”Daily News. New York. Archivedfrom the original on 18 April 2012.
  71. ^ “Pulseless Pumps & Artificial Hearts”Archived from the original on 7 March 2016.
  72. ^ European-Hospital. “The pulseless life on healthcare in europe”. Archived from the original on 5 October 2011. Retrieved 14 April 2011.
  73. ^ Dan Baum: No Pulse: How Doctors Reinvented The Human Heart Archived 2012-11-04 at the Wayback Machine. 2012-02-29.
  74. ^ Imachi K, Chinzei T, Abe Y, Mabuchi K, Imanishi K, Yonezawa T, Kouno A, Ono T, Atsumi K, Isoyama T (1991). “A new pulsatile total artificial heart using a single centrifugal pump”. ASAIO Trans37(3): M242-3. PMID 1751129.
  75. ^ “New Artificial Heart is Made of Foam”Popular Science. 1 October 2015. Archived from the original on 5 December 2015.
  76. ^ Prolonged Assisted circulation after cardiac or aortic surgery. Prolonged partial left ventricular bypass by means of intracorporeal circulation. This paper was finalist in The Young Investigators Award Contest of the American College of Cardiology. Denver, May 1962 Am. J. Cardiol. 1963, 12:399–404
  77. Jump up to:a b Mitka Mike (2001). “Midwest Trials of Heart-Assist Device”. Journal of the American Medical Association286 (21): 2661. doi:10.1001/jama.286.21.2661.
  78. ^ FDA APPROVES TWO PORTABLE HEART-ASSIST DEVICES Archived 2007-06-14 at the Wayback Machine at
  79. ^ An Artificial Heart That Doesn’t Beat at
  80. ^ “Berlin Heart”. Archived from the original on 16 October 2007. Retrieved 29 August 2007. (28 August 2007), Capital Health, Edmonton (archived from “Berlin Heart”. Archived from the original on 27 September 2007. Retrieved 29 August 2007. the original) on 2007-10-01.
  81. ^ “Newly approved Berlin Heart helps patients waiting for a transplant – Vector”. 30 December 2011.
  82. ^ Fraser, Charles D.; Jaquiss, Robert D.B.; Rosenthal, David N.; Humpl, Tilman; Canter, Charles E.; Blackstone, Eugene H.; Naftel, David C.; Ichord, Rebecca N.; Bomgaars, Lisa; Tweddell, James S.; Massicotte, M. Patricia; Turrentine, Mark W.; Cohen, Gordon A.; Devaney, Eric J.; Pearce, F. Bennett; Carberry, Kathleen E.; Kroslowitz, Robert; Almond, Christopher S. (2012). “Prospective Trial of a Pediatric Ventricular Assist Device”. New England Journal of Medicine367 (6): 532–541. doi:10.1056/nejmoa1014164PMID 22873533.
  83. ^ “News – Texas Children’s Hospital”Archived from the original on 25 April 2013.

External links[edit]


Navigation menu




In other projects



Edit links



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s